Company intelligence
EffRx Pharmaceuticals SA
We address unmet medical needs to improve patient outcomes and quality of life
About EffRx Pharmaceuticals SA
EffRx Pharmaceuticals is a Swiss commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications. EffRx’s lead commercialized product, Binosto® for the treatment of osteoporosis, is successfully commercialized by Licensees across US, European, Asian and Middle Eastern countries. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for a pipeline asset. EffRx is a member of the World Orphan Drug Alliance (WODA - www.woda-alliance.com).
Verified activity
Signals from EffRx Pharmaceuticals SA
3 published signals
Strategy & Corporate Development
EffRx Pharmaceuticals SA is seeking partners to commercialize Binosto® in the US, Latin America, and selected Asian markets, including South Korea.
Reported by EffRx Pharmaceuticals SA
Presence & Recognition
EffRx Pharmaceuticals SA is attending CPHI Milan from 6 to 8 October 2026 to explore in-licensing and partnership opportunities for rare diseases, endocrinology, metabolic and musculoskeletal disorders in Switzerland and Europe.
Reported by EffRx Pharmaceuticals SA
Partnerships
EffRx Pharmaceuticals SA announced a partnership with Androlabs to bring innovative therapies to patients with testosterone deficiency across Switzerland.
Reported by EffRx Pharmaceuticals SA